Loading
A paediatric oncologist at Tata Memorial who led the leukaemia arm of India's first CAR-T trials and runs national childhood leukaemia protocols.
Gaurav Narula is a paediatric oncologist at Tata Memorial Hospital whose work spans childhood acute lymphoblastic leukaemia protocols adapted to Indian conditions, the Indian Childhood Collaborative Leukaemia group trials and the clinical development of talicabtagene autoleucel (NexCAR19), for which he was an investigator and an author of the published real-world series. He also works on infection control and supportive care in low-resource paediatric oncology.
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
Shares Talicabtagene autoleucel, Tata Memorial Centre, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel, Tata Memorial Centre.
Shares ImmunoACT, Talicabtagene autoleucel, CAR-T cell therapy.
Shares Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel, CAR-T cell therapy.
Shares Talicabtagene autoleucel, CAR-T cell therapy, Acute lymphoblastic leukaemia.